Professor David Ebsworth, PhD has been Chairman of Actimed Therapeutics since April 2018 and has also invested in the Company. David has 40 years of experience in the Healthcare industry and is a past CEO of Galenica AG, Vifor Pharma AG and past global head of the Pharmaceutical Division of Bayer AG. David has chaired numerous private and public pharmaceutical companies and also served on numerous boards as either chairman of the audit, remuneration or nominations and governance committees. David currently serves as Chairman of Verona Pharma PLC which is listed on the Nasdaq stock exchange.

Robin Bhattacherjee BSc (Hons) joined Actimed Therapeutics as CEO in August 2019. Robin was previously with Actelion from 2009 and was the General Manager for the UK and Ireland Affiliate and a member of the European Management Team.
 
Robin served on the ABPI Board of Management from 2011 – 2017 as one of the elected Small Companies Group representatives, with a particular interest in medicines that come under specialised commissioning. Prior to Actelion, Robin was the General Manager for CV Therapeutics Europe (CVT) from 2004 to mid-2009, prior to the acquisition of the Company by Gilead. Responsibilities included delivering the European licencing and pre-marketing objectives for the product portfolio and the build and management of European affiliates. He also played a major role in successful European business development activities. Robin joined CVT from Sanofi-Synthélabo UK, where he was Head of Marketing and he also sat on the Irbesartan Global Strategy Team.
 
From 1986 to 2002, Robin held a variety of positions at Bayer including Marketing Manager and National Sales Manager in the UK and he was a Director in Bayer’s Global Strategic Marketing Group. During his career, Robin has been involved in several product launches both in the UK and Europe. Robin grew up in the North West of England and has an honours degree in Biological Sciences gained at University of London.

Professor Stefan Anker MD, PhD, co-founded Actimed Therapeutics in 2017, having previously founded Myotec (later renamed PsiOxus Therapeutics). Stefan has 30 years academic research experience in heart failure, cachexia and clinical trials with positions at Royal Brompton Hospital and Imperial College in London as well as University Göttingen and Charité Berlin. Stefan has been a tenured University-Professor in Germany since 2007, leading a highly active research group, and he is founding Editor-in-Chief of two successful scientific journals (including the Journal of Cachexia, Sarcopenia and Muscle).  Stefan was Vice President of the European Society of Cardiology (ESC) from 2016 to 2018, and served on the ESC board from 2012 to 2018. He has served on the board of the Heart Failure Association (HFA) of the ESC since 2006; and was HFA President from 2012 to 2014.

Professor Andrew Coats MBA, DSc, DM, co-founded Actimed Therapeutics in 2017, having  previously founded Myotec (later renamed PsiOxus Therapeutics). Andrew has over 30 years of experience as an academic manager, having been both Dean of Medicine and Deputy Vice-Chancellor at the University of Sydney and head of Clinical Cardiology at Imperial College and the Royal Brompton Hospital in London. Andrew also served as CEO of the Norwich Research Park in the UK. Andrew is an experienced board director and chairman with an MBA from London Business School. He has over 20 years of experience of company boards in roles including audit, remuneration, nominations and governance committees in biotechnology, publishing health care and education, including the George Institute of International Health, the Woolcock Institute, Lone Star Heart, Myotec, PsiOxus, Radcliffe Group, ESN Cleer and Faraday (Australia). Andrew has been on the board of the Heart Failure Association (HFA) of the ESC since 2012 and will be its President from 2020 to 2022.  He has been a member of over 20 international clinical trial steering committees in the fields of heart failure and cachexia and has over 700 career research papers, 95,000 citations and an h-Index of 130.

Atish Majumdar has over 24 years’ experience in India’s Pharmaceutical market including Go-to Market, General Management and Operational Leadership roles. Atish is President (Sales and Marketing) at Mankind Pharma’s Specialty Businesses in India and has successfully implemented digital interventional and people developmental strategies to transform business process and outcomes.

Prior to joining Mankind, Atish worked at Lupin Limited as Vice President and Cluster Head of Sales, Marketing and Training where he steered multiple strategic business units in India that operated in Cardiology, CNS and Oncology. Additionally, Atish led business operations in Sri Lanka and Bangladesh.

Atish graduated in Chemistry from Calcutta University and holds a Post Graduate Degree in Management from the Amity Business School. He also holds Certifications in General Management from Indian Institutes of Management, Harvard Business School and Wharton University.

Frank Misselwitz MD, PhD is Actimed’s Chief Medical Officer, located at the company’s German subsidiary. He joined the Company from Bayer AG, where he was Corporate Vice President and Therapeutic Area Head in clinical development. With a background in academia and industry, he has over 30 years extensive pharmaceutical industry experience. Frank supported the development of Humira ($20billion in 2018) at Knoll AG and Abbott and has completed development of multiple cardiovascular drugs (including rivaroxaban). Frank has been a longstanding member of the Scientific Advisory Board at the German Centre for Cardiovascular Research and the Centre for Thrombosis and Haemostasis University of Mainz Germany; he has extensive clinical research experience including the landmark COMPASS trial. His previous academic research experience was gained in UK, USA, Germany and Russia and he is the author of over 250 publications, has a cumulated impact factor of 1200 and a Hirsch-Index of 67. Frank is also a recipient of the highly prestigious German Future Prize for his work on Xarelto, this was awarded by the German Federal President in 2009.

Martin Walton initially spent 25 years in global investment banking and asset management, in UK, USA and Europe, culminating in a position as Vice Chair responsible for Wholesale and Commercial Banking for Europe and Asia-Pacific at Toronto-Dominion Bank.

Since 2009, Martin has been an active VC / PE investor, portfolio manager, and advisor in life sciences working with several of the largest investors in the sector.  This has involved holding a number of executive positions (Executive Chairman, CEO, CFO), completing transactions with over 25 companies (spinouts, financing rounds, M&A, IPOs, licensing deals, divestitures and trade sales) and raising over £1bn in investment and co-investment capital. He is Chairman and CEO of Bradshaw Consulting Limited, a strategic advisory group assisting companies and shareholders in creating, generating and realising value from investments in the life sciences sector.

Originally CEO of Excalibur Fund Management, Martin is a co-founder of LSE-listed Arix Bioscience plc (LSE: ARIX), of Arthurian Life Sciences Limited and of Excalibur Medicines Ltd. He is currently an investor / Director at Interrad Medical LLC, developer of the SecurAcath catheter securement device (now centrally purchased as the standard of care in the NHS); of AIM-listed Reneuron Plc (AIM: RENE), a UK-based leader in exosomes technologies, and of the Liverpool Life Sciences Accelerator Partnership.

In addition, he has extensive Governance, Oversight, Audit Committee and Risk Committee experience as well as specific experience in start-up, growth strategies (organic and acquisition), financing, turnaround and consolidation strategies in the healthtech, biotech and medtech sectors.

Stefan Wohlfeil, MD, has over 35 years of experience in the pharmaceutical and biotech industry. Most recently he was Chief Medical Officer and Head of R&D at Vifor Pharma with responsibility for preclinical and clinical R&D, regulatory and medical affairs as well as drug safety.  Prior to that he was Head of Clinical Research at Novartis OTC. He also has experience as founder and CEO of two start-up companies in the oncology area, one of which was based in Tokyo. Stefan started his career at Bayer Pharma, where he worked for over 20 years in discovery research and preclinical and clinical development in Germany, USA and Japan. Stefan holds a Medical Doctor’s degree from the University of Düsseldorf, Germany.